ESR1 and neoplasm: In line with these clinical observations, in preclinical experiments with xenografts of MCF7 cells and an ER+ patient-derived xenograft (PDX) model, when treatment was withdrawn, the tumors grew back and reached tumor volumes that were approximately 2.3-fold larger (50).